Privia Health Group (PRVA) closed at $22.41 on October 23, 2026, down 2.1% from the previous close, on volume of 626,965 shares (30-day average 1,250,518).
Data as of October 23, 2026.
No headlines found.
Privia Health to Report Third Quarter 2026 Results on Thursday, November 5
Globe Newswire (Thu, 8-Oct 9:00 AM ET)
Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors
Globe Newswire (Tue, 18-Aug 9:00 AM ET)
Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results
Globe Newswire (Thu, 6-Aug 6:00 AM ET)
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.
Privia Health Group trades on the NASDAQ stock market under the symbol PRVA.
As of October 26, 2026, PRVA stock price declined to $22.02 with 401,259 million shares trading.
PRVA has a beta of 0.40, meaning it tends to be less sensitive to market movements. PRVA has a correlation of 0.02 to the broad based SPY ETF.
PRVA has a market cap of $2.81 billion. This is considered a Mid Cap stock.
Last quarter Privia Health Group reported $633 million in Revenue and $.19 earnings per share. This beat revenue expectation by $36 million and missed earnings estimates by -$.02.
In the last 3 years, PRVA traded as high as $28.82 and as low as $15.92.
The top ETF exchange traded funds that PRVA belongs to (by Net Assets): IJR, VTI, IWM, VB, VBK.
PRVA has underperformed the market in the last year with a return of -14.9%, while the SPY ETF gained +15.0%. In the last 3 month period, PRVA fell short of the market, returning -11.8%, while SPY returned +3.9%. However, in the most recent 2 weeks PRVA has outperformed the stock market by returning +5.6%, while SPY returned -1.7%.
PRVA support price is $21.99 and resistance is $22.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRVA shares will trade within this expected range on the day.
